To investigate this, they conducted experiments where PBMCs from HC and IBD patients at different stages of disease activity were incubated with two different biological drugs: anti-TNFα (golimumab) and anti-IL12/23 (ustekinumab). This evidence concerns the gene TNF and inflammatory bowel disease.